Cargando…

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?

SIMPLE SUMMARY: The recent approval of the drug Pembrolizumab for patients with the triple-negative subtype of breast cancer highlights the search for new markers to indicate the treatment. Due to their broad regulatory role and tissue specificity, lncRNA molecules can rise as biomarkers. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathias, Carolina, Kozak, Vanessa Nascimento, Magno, Jessica Maria, Baal, Suelen Cristina Soares, dos Santos, Victor Henrique Apolonio, Ribeiro, Enilze Maria de Souza Fonseca, Gradia, Daniela Fiori, Castro, Mauro Antonio Alves, Carvalho de Oliveira, Jaqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572024/
https://www.ncbi.nlm.nih.gov/pubmed/37835376
http://dx.doi.org/10.3390/cancers15194682
_version_ 1785120139311579136
author Mathias, Carolina
Kozak, Vanessa Nascimento
Magno, Jessica Maria
Baal, Suelen Cristina Soares
dos Santos, Victor Henrique Apolonio
Ribeiro, Enilze Maria de Souza Fonseca
Gradia, Daniela Fiori
Castro, Mauro Antonio Alves
Carvalho de Oliveira, Jaqueline
author_facet Mathias, Carolina
Kozak, Vanessa Nascimento
Magno, Jessica Maria
Baal, Suelen Cristina Soares
dos Santos, Victor Henrique Apolonio
Ribeiro, Enilze Maria de Souza Fonseca
Gradia, Daniela Fiori
Castro, Mauro Antonio Alves
Carvalho de Oliveira, Jaqueline
author_sort Mathias, Carolina
collection PubMed
description SIMPLE SUMMARY: The recent approval of the drug Pembrolizumab for patients with the triple-negative subtype of breast cancer highlights the search for new markers to indicate the treatment. Due to their broad regulatory role and tissue specificity, lncRNA molecules can rise as biomarkers. Therefore, this review aimed to raise possible lncRNAs that act as an indication for the treatment. In addition, we searched for lncRNAs already discussed in other types of cancer that deserve to be better investigated in the context of breast cancer. ABSTRACT: As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is a growing demand for biomarkers that can distinguish which patients are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by a lack of therapeutic targets, pembrolizumab approval for high-risk early-stage disease occurred regardless of PD-L1 status, which keeps the condition in a biomarker limbus. In this review, we highlight the participation of long non-coding RNAs (lncRNAs) in the regulation of the PD-1/PD-L1 pathway, as well as in the definition of prognostic immune-related signatures in many types of tumors, aiming to shed light on molecules that deserve further investigation for a potential role as biomarkers. We also conducted a bioinformatic analysis to investigate lncRNAs already investigated in PD-1/PDL-1 pathways in other cancer types, considering the TNBC molecular context. In this sense, from the generated data, we evidence here two lncRNAs, UCA1 and HCP5, which have not yet been identified in the context of the tumoral immune response in breast cancer. These candidates can be further explored to verify their use as biomarkers for ICI response. In this article, we present an updated review regarding the use of lncRNA as biomarkers of response to ICI, highlighting the versatility of using these molecules.
format Online
Article
Text
id pubmed-10572024
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105720242023-10-14 PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated? Mathias, Carolina Kozak, Vanessa Nascimento Magno, Jessica Maria Baal, Suelen Cristina Soares dos Santos, Victor Henrique Apolonio Ribeiro, Enilze Maria de Souza Fonseca Gradia, Daniela Fiori Castro, Mauro Antonio Alves Carvalho de Oliveira, Jaqueline Cancers (Basel) Review SIMPLE SUMMARY: The recent approval of the drug Pembrolizumab for patients with the triple-negative subtype of breast cancer highlights the search for new markers to indicate the treatment. Due to their broad regulatory role and tissue specificity, lncRNA molecules can rise as biomarkers. Therefore, this review aimed to raise possible lncRNAs that act as an indication for the treatment. In addition, we searched for lncRNAs already discussed in other types of cancer that deserve to be better investigated in the context of breast cancer. ABSTRACT: As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is a growing demand for biomarkers that can distinguish which patients are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by a lack of therapeutic targets, pembrolizumab approval for high-risk early-stage disease occurred regardless of PD-L1 status, which keeps the condition in a biomarker limbus. In this review, we highlight the participation of long non-coding RNAs (lncRNAs) in the regulation of the PD-1/PD-L1 pathway, as well as in the definition of prognostic immune-related signatures in many types of tumors, aiming to shed light on molecules that deserve further investigation for a potential role as biomarkers. We also conducted a bioinformatic analysis to investigate lncRNAs already investigated in PD-1/PDL-1 pathways in other cancer types, considering the TNBC molecular context. In this sense, from the generated data, we evidence here two lncRNAs, UCA1 and HCP5, which have not yet been identified in the context of the tumoral immune response in breast cancer. These candidates can be further explored to verify their use as biomarkers for ICI response. In this article, we present an updated review regarding the use of lncRNA as biomarkers of response to ICI, highlighting the versatility of using these molecules. MDPI 2023-09-22 /pmc/articles/PMC10572024/ /pubmed/37835376 http://dx.doi.org/10.3390/cancers15194682 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mathias, Carolina
Kozak, Vanessa Nascimento
Magno, Jessica Maria
Baal, Suelen Cristina Soares
dos Santos, Victor Henrique Apolonio
Ribeiro, Enilze Maria de Souza Fonseca
Gradia, Daniela Fiori
Castro, Mauro Antonio Alves
Carvalho de Oliveira, Jaqueline
PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title_full PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title_fullStr PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title_full_unstemmed PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title_short PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
title_sort pd-1/pd-l1 inhibitors response in triple-negative breast cancer: can long noncoding rnas be associated?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572024/
https://www.ncbi.nlm.nih.gov/pubmed/37835376
http://dx.doi.org/10.3390/cancers15194682
work_keys_str_mv AT mathiascarolina pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT kozakvanessanascimento pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT magnojessicamaria pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT baalsuelencristinasoares pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT dossantosvictorhenriqueapolonio pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT ribeiroenilzemariadesouzafonseca pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT gradiadanielafiori pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT castromauroantonioalves pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated
AT carvalhodeoliveirajaqueline pd1pdl1inhibitorsresponseintriplenegativebreastcancercanlongnoncodingrnasbeassociated